TransMedics Group, Inc. 8-K

What Happened

• TransMedics Group, Inc. (TMDX) held its 2026 Annual Meeting of Shareholders on May 20, 2026 and filed an 8-K on May 21, 2026 reporting the results.
• Eight director nominees were elected to serve until the 2027 annual meeting: Waleed Hassanein, M.D.; James R. Tobin; Edward M. Basile; Thomas J. Gunderson; Edwin M. Kania, Jr.; Stephanie Lovell; Merilee Raines; and David Weill, M.D. (see vote tallies below). Shareholders also voted on management proposals including an advisory vote on executive compensation, an amendment to the 2019 Stock Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditor.

Key Details

• Director election vote totals (For / Against / Abstain; Broker Non-Votes: 4,632,985 for each nominee):
  • Waleed Hassanein, M.D.: 23,925,335 / 122,999 / 15,389
  • James R. Tobin: 23,594,322 / 453,100 / 16,301
  • Edward M. Basile: 22,395,787 / 1,651,466 / 16,470
  • Thomas J. Gunderson: 23,667,347 / 380,233 / 16,143
  • Edwin M. Kania, Jr.: 23,603,708 / 443,438 / 16,577
  • Stephanie Lovell: 23,932,921 / 111,757 / 19,045
  • Merilee Raines: 23,908,647 / 140,715 / 14,361
  • David Weill, M.D.: 23,842,978 / 204,717 / 16,028
• Advisory (non-binding) vote on executive compensation (say-on-pay): For 22,871,647; Against 1,161,181; Abstain 30,895; Broker Non-Votes 4,632,985.
• Amendment to the Amended and Restated 2019 Stock Incentive Plan was approved: For 17,265,369; Against 6,758,882; Abstain 39,472; Broker Non-Votes 4,632,985. The amendment is filed as Exhibit 10.1 to the 8-K.
• Ratification of independent auditor: PricewaterhouseCoopers LLP was ratified for fiscal 2026: For 28,030,696; Against 648,359; Abstain 17,653.

Why It Matters

• Board continuity: Election of all eight nominees maintains the board’s composition and governance continuity through the 2027 annual meeting.
• Shareholder approval signals: A strong majority supported the company’s executive compensation plan (say-on-pay), indicating broad shareholder support for pay practices. The stock incentive plan amendment also passed, which may affect future equity awards and potential dilution—investors should review the filed amendment (Exhibit 10.1) for details on share authorization or other changes.
• Audit continuity: Ratification of PwC as auditor preserves the company’s external audit relationship for fiscal 2026, a routine but important governance step.

Keywords: annual meeting, director election, say-on-pay, stock incentive plan amendment, auditor ratification, TransMedics.